doi.org/10.1016/s2352-3018(22)00041-8
Original paper

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

..., Mduduzi Masilela
5
The Lancet HIV13.00
Volume: 9, Issue: 5, Pages: e309 - e322
Published: May 1, 2022
Paper Fields
Paper Details
Title
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
DOI
doi.org/10.1016/s2352-3018(22)00041-8
Published Date
May 1, 2022
Journal
The Lancet HIV
Volume
9
Issue
5
Pages
e309 - e322
© 2025 Pluto Labs All rights reserved.